# Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors

> **NCT03261011** · PHASE1 · COMPLETED · sponsor: **Akesobio Australia Pty Ltd** · enrollment: 119 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **BIOLOGICAL:** AK-104

## Key facts

- **NCT ID:** NCT03261011
- **Lead sponsor:** Akesobio Australia Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-03
- **Primary completion:** 2021-08-27
- **Final completion:** 2023-04-13
- **Target enrollment:** 119 (ACTUAL)
- **Last updated:** 2025-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03261011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03261011, "Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03261011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*